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Abstract – The paper discusses undesirable interactions of non-
steroidal anti-inflammatory drugs (NSAIDs) with other drugs. Atten-
tion is paid to the toxicity of those medications. The particular focus 
is on the NSAIDs’ impact on the gastrointestinal tract mucosa (espe-
cially in the stomach and duodenum).  
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Streszczenie – Autorzy omówili niepożądane interakcje niesterydo-
wych leków przeciwzapalnych (NLPZ) w innymi lekami, zwrócili 
uwagę na toksyczne działanie tych specyfików.  Dokładniej omówio-
no mechanizm działania NLPZ na błonę śluzową przewodu pokar-
mowego (zwłaszcza żołądka i dwunastnicy). 
 
Słowa kluczowe - niesterydowe leki przeciwzapalne, interakcji, tok-
syczne działanie, uszkodzenia śluzówki przewodu pokarmowego. 
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I. UNDESIRABLE OUTCOMES OF AN NSAID 
THERAPY 
 
ndesirable outcomes of an NSAID therapy may pertain to 
patients of all ages. Nevertheless, the elderly are especial-
ly exposed to the undesirable effects of using NSAIDs. 
That is related to any possible disorders related to the absorp-
tion, distribution, metabolism and excretion of NSAIDs. The 
changes in renal and hepatic flow, the changed percentage of 
adipose tissue in the total body mass as well as different num-
ber and sensitivity of cell receptors may all be undesirably 
caused by the sustained NSAID treatment [1,2,3]. One has to 
remember that NSAIDs also may interact negatively with 
many other drugs, which makes the undesirable effects even 
more serious (Table 1). 
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The undesirable effects of NSAIDs may pertain to varius 
systems and organs. Their toxicity may cause: 
 Renal impairment resulting from taking NSAIDs; it is 
mostly not clinical and relieves soon after the patient 
stops taking the drug. However, acute renal failure 
sometimes occurs. The drugs in question may inhibit 
the prostaglandin synthesis, which causes white layer 
ischemia, which in turn provides the foundations for 
drug-induced nephropathy lesions. Patients who have 
a prior history of renal impairment or cardiac 
dysrhythmia, salt and water retention may become a 
clinical problem. The literature of the field also de-
scribes cases of interstitial nephritis and, more rarely, 
glomerulonephritis [1,4,6,7]. 
 
 Bronchospasm. Although it occurs rarely as a conse-
quence of NSAID therapy, it is difficult to be pre-
vented, especially if a patient is susceptible to a reac-
tion of that kind. It seems that certain drugs, such as 
azapropazone and nabumetone, are free of such ef-
fects [1,4,5]. 
 
 Gristle and bone damage. The inhibition of the prosta-
glandin synthesis by strong NSAIDs has been be-
lieved to quickly cause damage to the head of femur 
(“indomethacin hip”). Currently, however, this mech-
anism is considered doubtful, as is the general thesis 
on gristle and bone damage caused by the drugs. 
While in vitro studies and tests on animals have 
shown that some NSAIDs do inhibit the synthesis of 
proteoglycans, others have been found to stimulate 
this synthesis, which however cannot justify the view 
endorsed by some authors that certain NSAIDs ( e.g. 
azapropazone, diclofenac, sulindac) protect gristle  
[4,5,8,9]. 
 
 Certain NSAIDs (especially aspirin) may cause head-
aches and dizziness as well as tinnitus, which is relat-
ed to the drug plasma concentration. Confusion and 
psychomotor function impairment also occur, mainly 
after indomethacin, which has the most serious con-
sequences for the elderly. All undesirable conse-
quences are dependent on the dose, although high tol-
erance and cross-tolerance are sometimes observed 
[4,7]. 
 
 The most common idiosyncratic effect of NSAIDs is a 
skin rash, even though its frequency is dependent on 
the particular drug. Usually, the most serious skin re-
actions occur after fenbufen [1,4,7]. 
 The use of NSAIDs is generally accompanied by insig-
nificant and reversible increase in hepatic enzymes. 
However, cases of toxic hepatitis induced by aspirin, 
diclofenac, fenoprofen, naproxen have been de-
scribed; and the use of sulindac may lead to reversi-
ble cholestatic jaundice [1,4,5]. 
 
 The most common and the most life-threatening unde-
sirable effect of sustained NSAID treatment is related 
to the gastrointestinal tract [1,4,10,11,12]. For in-
stance, the average risk of complications in gastroin-
testinal tract, rated in the rank system, is: 1.1 for ibu-
profen, 2.9 for diclofenac, 5 for diflunisal,  3 for 
fenoprofen, 2.7 for salicylic acid, 4.4 for sulindac, 3.4 
for naproxen, 4 for indomethacin, 5.1 for piroxicam, 
4.7 for ketoprofen, 6.5 for tolmetin and 7.5 for 
azapropazone [5,6].  
 Unfavourable effects of NSAIDs on gastrointestinal 
tract are most frequently reflected by dyspeptic symp-
toms such as nausea, flatulence, abdominal pain and 
defecation rhythm disorders. However, in some of the 
cases, dangerous damage to the mucosa of the gastro-
intestinal tract, duodenum and intestines occurs. The 
risk of drug-induced gastric ulceration pertains to 20-
30% of patients treated with NSAIDs. With reference 
to duodenum ulceration, the percentage is 5-10%. 
These ulcerations often are clinically “mute”, which 
often makes their complications (bleeding, perfora-
tion) the first symptoms of the disease [1,2,5,12]. 
 Nearly 70% of deaths resulting from the complications 
of gastric and duodenal ulcerations are the cases of 
NSAID-treated patients. The likelihood of dying of 
ulceration-related bleeding is four times as high in the 
elderly treated with NSAIDs as in those who do not 
take them [ 4,7]. 
 
 
II. THE MECHANISM OF THE DAMAGING IMPACT 
OF NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS ON GASTRIC 
MUCOSA 
 
The influence of NSAIDs on the mucosa of the upper gas-
trointestinal tract has been widely studied experimentally and 
clinically. It has been observed that gastric barrier is damaged 
by various complex mechanisms, regardless of where the drugs 
enter the organism [13,14,15]. The presumable mechanism of 
the mucosa damage caused salicylic acid is shown in figure 1. 
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Figure1. The mechanism of the effect of acetylsalicylic acid on gastric mucosa [13,14,15] 
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Important as they are, local effects of NSAIDs do not 
seem pivotal with regard to the mucosal damage to up-
per gastrointestinal tract [11,13]. 
This is defended by the fact that such damage may be 
also inflicted by NSAIDs applied parenterally [15]. 
The main systemic mechanism of such damage may be 
associated with the NSAID effects consisting in the in-
hibition of prostaglandin synthesis in the stomach wall 
[11,14]. In physiological conditions, the protective ef-
fects of prostaglandins on mucosa are constituted by 
several mechanisms [14]: 
  they protect the epithelial and glandular cells from 
the effects of cytotoxic factors 
 they stimulate the release of bicarbonates 
 they increase the mucus production and make it 
more resistant to the acid 
 they inhibit the secretion of hydrochloric acid 
 they protect the surface epithelium proliferation 
zone 
 they sustain the functionality of microcirculation 
and the integration ability of vascular walls 
 
In normal conditions, the cyclooxygenase 1 (COX-1) 
enzyme is employed in the production of prostaglandins 
in stomach walls. Many NSAIDs used nowadays are 
strong inhibitors of this enzyme.  
Other mechanisms related to the harmful systemic ef-
fects of NSAIDs should be considered as well – for in-
stance, a decrease in platelet aggregation (the inhibition 
of thromboxane A2 synthesis in thrombocytes), which 
causes the deterioration of haemorrhagic lesions or the 
inhibition of the angiogenesis process. The clinical con-
sequences of that might be the difficulty of ulceration 
healing in patients who use NSAIDs chronically [12,14].  
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